ID   MCF-7/RTx6
AC   CVCL_4V43
SY   MCF-7 Rtx6; RTx6; RTX6; RTx-6; Rtx-6
DR   cancercelllines; CVCL_4V43
DR   Wikidata; Q54904377
RX   PubMed=6574477;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=6574477; DOI=10.1073/pnas.80.11.3158;
RA   Faye J.-C., Jozan S., Redeuilh G., Baulieu E.-E., Bayard F.;
RT   "Physicochemical and genetic evidence for specific antiestrogen
RT   binding sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:3158-3162(1983).
//